Written By Are you interested in investing in the booming dermatology industry? Look no further than EQT’s upcoming IPO for Galderma. As one of the leading pharmaceutical companies focused on skin health, Galderma is poised to revolutionize the skincare market with innovative treatments and a commitment to sustainability. In this post, we’ll take a closer look at what makes Galderma such an exciting investment opportunity and what it could mean for the future of dermatology as a whole. So let’s dive in!
What is Galderma?
Galderma is a global pharmaceutical company that specializes in the research, development, and commercialization of dermatological solutions. The company has a portfolio of over 60 products that are distributed in more than 100 countries. Galderma is headquartered in Lausanne, Switzerland and has a network of 11 research and development centers around the world.
The company was founded in 1981 as a joint venture between Nestlé and L’Oréal. In 2015, Galderma was acquired by EQT Partners for €4 billion. EQT is a leading private equity firm with a focus on investments in mid-market companies.
Galderma’s mission is to improve the health and well-being of people with skin conditions. The company’s products are used to treat a variety of conditions, including acne, rosacea, psoriasis, eczema, and other skin disorders. Galderma is committed to innovation and strives to bring new solutions to market that improve patient outcomes.
The company has a strong track record of success in bringing new products to market. In 2019, Galderma launched two new products: Cetaphil Redness Relieving Daily Facial Moisturizer SPF 30 and Restylane Silk Lip Enhancement. These two products have been well-received by patients and physicians alike and are helping to solidify Galderma’s position as a leader in the dermatology market.
EQT’s investment in Galderma
EQT’s investment in Galderma is a smart move for the future of dermatology investment. The company has a strong portfolio of products and a proven track record of success. EQT’s support will help to fuel continued growth and expansion.
Galderma is a global leader in medical solutions for the skin, hair and nails. The company offers a comprehensive range of products and services that are backed by science and delivered by experienced professionals. Galderma’s products are sold in over 100 countries and its research and development facilities are located in Europe, North America and Asia Pacific.
Galderma’s product portfolio includes prescription drugs, over-the-counter treatments, aesthetic solutions and consumer health products. The company’s key therapeutic areas are acne, rosacea, psoriasis, eczema, skin cancer and aesthetics. Galderma has a strong focus on research and development, with over 500 scientists working on new products and solutions.
EQT’s investment will help to support Galderma’s continued growth and expansion. This will include investments in research and development, as well as new product launches. EQT’s backing will also enable Galderma to accelerate its digital transformation journey. This will involve investments in data analytics, e-commerce and digital marketing initiatives.
The future of dermatology investment
The future of dermatology investment is looking very bright. The recent IPO of Galderma, a leading provider of innovative medical solutions for the treatment of skin conditions, is a great example of this. With a strong focus on research and development, Galderma is well-positioned to continue delivering new and improved treatments for patients around the world.
EQT’s investment in Galderma is a vote of confidence in the company’s future prospects. We believe that Galderma has the potential to become a global leader in dermatology, and we are excited to be a part of its journey.
Galderma’s products and services
Galderma is a global pharmaceutical company specializing in the research, development, and commercialization of dermatological treatments. The company offers a broad range of products and services for the treatment of acne, rosacea, psoriasis, eczema, and skin cancer. Galderma also provides a variety of cosmeceuticals for the prevention and treatment of premature aging and sun-damaged skin. In addition to its line of prescription medications, Galderma markets over-the-counter products, such as cleansers, moisturizers, sunscreens, and anti-aging serums.
Galderma’s product portfolio includes some of the most widely prescribed dermatological treatments in the world. The company’s flagship product, Oracea®, is an oral therapy for the treatment of acne vulgaris. Other popular products include Cetaphil®, a line of gentle skincare products; Mirvaso®, a topical gel for the treatment of rosacea; Differin®, an acne treatment gel; and Epiduo®, a topical gel for the treatment of acne vulgaris and atrophic scars. Galderma also offers a variety of cosmeceuticals under the brands Cetaphil®DERMOTEC™ and Metrogel®1%.
Galderma’s R&D pipeline includes several promising new drugs for the treatment of acne, psoriasis, eczema, and skin cancer. The company is currently conducting clinical
The global dermatology market
The dermatology market is expected to grow at a compound annual growth rate (CAGR) of 6.3% from 2016 to 2024, according to a new report by Grand View Research, Inc. The global dermatology market is driven by the increasing prevalence of skin diseases, the growing aging population, and the rising awareness of skin care.
The report segments the global dermatology market by disease type, treatment type, and geography. By disease type, the market is classified into acne, psoriasis, eczema, skin cancer, and others. By treatment type, the market is divided into topical treatments, phototherapy, injectables/systemic therapy, and surgery.
Geographically, the global dermatology market is segmented into North America (U.S., Canada), Europe (Germany, U.K., France), Asia Pacific (China , India , Japan ), Latin America (Brazil), and Middle East & Africa (South Africa). North America held the largest share of the global dermatology market in 2016 due to the high prevalence of skin diseases in this region. However , Asia Pacific is expected to witness the highest CAGR during the forecast period owing to factors such as the growing aging population , rising awareness about skin care , and increasing disposable incomes .
Some of the key players operating in this market are Galderma S.A., Johnson & Johnson Services , Inc., Pfizer Inc., Valeant Pharmaceuticals International , Inc., Sanofi
Conclusion
EQT’s Galderma IPO offers investors a unique opportunity to invest in the future of dermatology and pharmaceuticals. By investing in this company, investors will be able to capitalize on one of the fastest growing markets in healthcare. Furthermore, they will also have access to innovative treatments that are transforming the way dermatologists treat their patients. With its strong portfolio and robust pipeline, we expect great things from EQT’s Galderma IPO in terms of profitability potential for investors.
